Group 1 - The core viewpoint of the news is that Weigao Bio has reached a trading limit with a price of 33.79 yuan, reflecting a 9.99% increase and a total market capitalization of 7.664 billion yuan [1] - Weigao Bio is actively investing in the cutting-edge fields of cell and gene therapy, establishing a public service platform that aligns with national biopharmaceutical industry policies, with a market potential exceeding 100 billion yuan [2] - The company has signed a $160 million technical cooperation agreement for blood products, which is expected to significantly enhance its international influence and future performance [2] Group 2 - Weigao Bio's first domestic SCIG product has received clinical trial acceptance, filling a domestic gap with substantial market potential, while similar overseas products have validated its feasibility [2] - The smart industrial base project, once fully operational, will achieve an annual output of 1,200 tons, greatly enhancing existing production capacity, and the company has been approved for eight new plasma station areas, enjoying regional exclusivity and a first-mover advantage [2] - The biopharmaceutical sector, particularly in cell and gene therapy, remains a market focus with broad development prospects, and on February 5, related stocks showed active performance, creating a certain sector linkage effect [2]